• <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
    来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置首页>技术资料首页>行业动态>新品动态>华大基因购128台Illumina HiSeq 2000新测序仪

    华大基因购128台Illumina HiSeq 2000新测序仪

    Illumina2010年1月22日 21:30 点击:5999

      华大基因
    Illumina公司近日宣布推出一种全新的测序仪- HiSeq 2000,其性能较Genome Analyzer有全面升级,体现在测序产量、易用性和经济性等方面。同时,该公司还宣布,他们已经签下了第一笔订单,华大基因订购了128台。

    Illumina公司的总裁Jay Flatley在2010年摩根大通保健大会表示:“HiSeq 2000既有Illumina和Solexa在边合成边测序上的优势,又融合了最新的光学和系?#25104;?#35745;。这些创新重新定义了测序的轨迹,将人类基因组的测序费用降至1万美元以下。”

    HiSeq 2000
    HiSeq 2000具有以下特点:

    • 前所未有的产量——HiSeq 2000能够在单次运行中产生200 Gb的数据,每天能产生25 Gb。该系统使用两个流动槽和一种新颖的双表面成像方法,能够使测序通量及实验灵活性提升到新的水?#20581;?br />
    • 突破性的用户体验——HiSeq 2000具有最简化和直观的单个操作员流程,启动运行仅需10?#31181;?#30340;手工操作时间。即插即用试剂,触摸?#20004;?#38754;,以及实时的运程运行监控,让仪器操作更简单。文库制备时96个样品的平行处理显著降低了手工操作时间和整体的费用。
    • 无可比拟的经济操作——研究人员以30倍的覆盖度对两个人类基因组进行测序,每个基因组的费用不到1万美元。HiSeq 2000能以单个或两个流动槽的模式运行,并同时运行需要不同读长的应用。

      Illumina将于下个月开始发货,并预计会对目前使用Genome Analyzer的用户实行以旧换新计划。?#36824;現latley表示Illumina会继续开发、制造并销售Genome Analyzer系统,让研究人员有更多的选择。

      华大基因的这笔订单是Illumina迄今为止签下的最大一笔。128台仪器中的大部分将放在新开的香港基因组?#34892;摹llumina将在今年第一季度开始安装仪器,剩下的仪器将会在接下来的三个季度?#26032;?#32493;交付。

      上个月,国家开发银行与华大基因签订了长期协议,为该研究所提供了15亿美元的贷款。华大基因表示将使用这笔钱为医疗保健、农业、生物能源及其它应用搭建科研及应用平台。

      华大基因副总裁张秀清表示:“我们的目标是与全世界合作,为整个社会的进步做出贡献。创建能增?#20248;?#19994;和粮食产量的解决方案是我们最关注的,以及更多区域特异的项目,比如中国个人基因组领域的开发。”

      Illumina新闻稿
      BGI Purchases 128 Illumina HiSeq(TM) 2000 Sequencing Systems

       

    Acquisition Puts Beijing Genomics Institute on Path to Become World's Largest Sequencing Facility

     

    SAN DIEGO, Jan 12, 2010 (BUSINESS WIRE) -- Illumina, Inc. (NASDAQ:ILMN) announced today that the BGI (formerly known as the Beijing Genomics Institute) has purchased 128 HiSeq 2000 sequencing systems, representing the largest single order for next-generation sequencing systems to date. Most of the units will be installed in BGI's new state-of-the-art genome center in Hong Kong.

    "BGI's investment in Illumina's new HiSeq 2000 system is an important step in our effort to develop a premier sequencing facility that serves scientists globally," said Xiuqing Zhang, vice president of BGI. "Our goal is to build partnerships and collaborations around the world that contribute to the overall improvement of our global society. Creating solutions that enhance agriculture and food production, for example, are a key focus for us, as well as more region-specific programs, such as the development of the personal genomics field in China."

    BGI is among the world's leading scientific organizations committed to understanding biology and medicine through the use of large-scale sequencing and bioinformatics analysis. BGI has research centers in the United States, Europe, and Hong Kong, and seven genome research centers in mainland China for scientific collaboration and sequencing services. Last month, BGI signed a long-term agreement with China Development Bank. The initial funding (1.5 billion US$) will help BGI build research and application platforms for sustainable development in healthcare, agriculture, bio-energy, environmental protection, and related fields.

    "We are deeply honored that BGI has selected Illumina as its partner for sequencing technology. Our company is strongly committed to helping the Institute achieve its ambitious vision of providing sequencing resources to public and private entities throughout the world," said Matt Posard, vice president of Global Sales at Illumina. "Illumina is thrilled that BGI selected our recently launched HiSeq 2000 sequencer to enable their vision."

    Installations of HiSeq 2000 systems will begin in the first quarter and continue over the subsequent three quarters. Revenue related to the sale of these instruments is expected to be recognized over the next three years. For more information about the HiSeq 2000 sequencing system, please visit Illumina's website at http://illumina.com/HiSeq2000.

    About Illumina

    Illumina (http://www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.

    Forward-Looking Statements

    This release contains forward-looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding when system installations are to begin and when revenue is expected to be realized. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in new product development and manufacturing and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update any forward-looking statements after the date of this release.

    SOURCE: Illumina, Inc.

    Illumina, Inc.
    Investors:
    Peter J. Fromen, 858-202-4507
    Sr. Director, Investor Relations
    [email protected]
    or
    Media:
    Wilson Grabill, 858-882-6822
    Senior Manager, Public Relations
    [email protected]

    (来源: Illumina )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://www.67994619.com,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为?#29260;?#30456;关权利。


    云南11选5技巧
  • <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
  • <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
    幸运飞艇计划人工在线全天免费版 中国.玛曲县.赛马会 北京快乐8任选一技巧 德甲的最新积分榜 11选5顺口溜 体彩甘肃11选5开奖 31选7旋转矩阵 黑龙江p62彩票 季后赛nba比分 幸运赛车计划2019 黑龙江福彩 湖北福彩30选5 125期湖南码报 年香港特码资料图 北京28官网开奖查询